Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large decline in short interest in February. As of February 13th, there was short interest totaling 18,363 shares, a decline of 27.8% from the January 29th total of 25,448 shares. Based on an average daily volume of 26,672 shares, the short-interest ratio is presently 0.7 days. Currently, 1.4% of the shares of the stock are sold short. Currently, 1.4% of the shares of the stock are sold short. Based on an average daily volume of 26,672 shares, the short-interest ratio is presently 0.7 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Trading of Sonoma Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Heron Bay Capital Management purchased a new position in Sonoma Pharmaceuticals in the 2nd quarter valued at $96,000. DRW Securities LLC lifted its stake in shares of Sonoma Pharmaceuticals by 257.2% in the fourth quarter. DRW Securities LLC now owns 60,977 shares of the company’s stock worth $222,000 after buying an additional 43,907 shares in the last quarter. Finally, McKinley Carter Wealth Services Inc. acquired a new position in Sonoma Pharmaceuticals during the fourth quarter worth about $41,000. 1.95% of the stock is currently owned by hedge funds and other institutional investors.

Sonoma Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ SNOA opened at $2.90 on Friday. The company’s 50-day simple moving average is $3.27 and its 200-day simple moving average is $3.74. Sonoma Pharmaceuticals has a 52-week low of $1.75 and a 52-week high of $6.92. The firm has a market cap of $5.02 million, a price-to-earnings ratio of -1.42 and a beta of 1.65.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its quarterly earnings results on Tuesday, February 10th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.06). Sonoma Pharmaceuticals had a negative return on equity of 42.56% and a negative net margin of 19.04%.The company had revenue of $4.35 million for the quarter, compared to analyst estimates of $5.47 million. Equities research analysts anticipate that Sonoma Pharmaceuticals will post -0.67 EPS for the current fiscal year.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.